Dynamics of immature subsets of dendritic cells during antiviral therapy in HLA-A24-positive chronic hepatitis C patients

J Gastroenterol. 2006 Aug;41(8):758-64. doi: 10.1007/s00535-006-1843-9.

Abstract

Background: The cellular immune response is important in chronic hepatitis C (CHC). To better understand its mechanism, we examined dendritic cells (DCs) and hepatitis C virus (HCV)-specific cytotoxic T cells (CTLs), which are thought to contribute to liver injury and viral clearance.

Methods: CHC patients received 24 weeks of interferon-alpha-based antiviral therapy. We analyzed time-sequential frequencies of peripheral DCs, classified as myeloid DCs (mDCs) or plasmacytoid DCs (pDCs), together with peptide major histocompatibility class I tetramers, epitope specific for HCV core 129-137 (t*24/c129) or HCV NS3 1296-1304 (t*24/ns1294), directly ex vivo.

Results: The mDC and pDC populations changed in parallel (P < 0.05), showing a significant transient decrease at weeks 12 and 16 during the therapy, and then recovering. However, neither of the tetramer results showed a direct correlation with the kinetics of peripheral DCs.

Conclusions: There is an apparent effect of antiviral therapy or a subsequent reduction of HCV on host immunity, but the effect may not include the induction of CTLs in CHC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use*
  • Dendritic Cells / immunology*
  • Female
  • Flow Cytometry
  • HLA-A Antigens / blood
  • HLA-A24 Antigen
  • Hepacivirus / immunology
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / immunology*
  • Humans
  • Immunity, Cellular / drug effects
  • Interferon-alpha / therapeutic use
  • Male
  • Middle Aged
  • Ribavirin / therapeutic use
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • Antiviral Agents
  • HLA-A Antigens
  • HLA-A24 Antigen
  • Interferon-alpha
  • Ribavirin